Welcome to our dedicated page for SRGA news (Ticker: SRGA), a resource for investors and traders seeking the latest updates and insights on SRGA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SRGA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SRGA's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced on April 10, 2023, that it received a notification from Nasdaq indicating it is no longer in compliance with the $10 million minimum stockholders’ equity requirement for continued listing. The notification does not immediately affect the trading of its common stock. The company has 45 days to submit a plan for compliance, which may include transferring its listing to the NASDAQ Capital Market. If accepted, Surgalign could be granted up to 180 days to demonstrate compliance. The company plans to submit this plan by May 25, 2023.
Surgalign focuses on digital health and innovative solutions for surgical care and operates in over 40 countries.
Surgalign Holdings, Inc. (NASDAQ: SRGA) reported Q4 and full-year 2022 results, highlighting a revenue decline to $20.6 million from $21.8 million year-over-year. GAAP gross margin was -13.6%, down from 56.5% in Q4 2021 due to inventory write-downs related to restructuring. Nonetheless, total operating expenses decreased significantly to $45.3 million from $105 million a year prior. The company successfully closed a $12 million offering and sold its Coflex product line for $17 million, boosting its cash position. Surgalign aims to achieve $30-$35 million in cash savings in 2023 and believes it can maintain liquidity through Q4 2023.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced plans to release its financial results for Q4 and full year 2022 after market close on March 30, 2023. A conference call will follow at 4:30 p.m. ET, accessible via phone or webcast. The company focuses on advancing digital health in the surgical landscape, with operations in the U.S. and approximately 50 countries. Surgalign aims to deliver superior clinical outcomes and has faced various forward-looking risks including financial stability, litigation, and integration challenges from recent acquisitions. Investor relations details are provided for further inquiries.